Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026

    UAE and Timor-Leste presidents discuss stronger bilateral ties

    November 16, 2026

    UAE President, Arab League chief discuss regional security

    November 14, 2026
    Arab EnquirerArab Enquirer
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Arab EnquirerArab Enquirer
    Home » Pfizer’s COVID-19 medicine Paxlovid hits the market at a steep $1,400, sparking concerns
    Health

    Pfizer’s COVID-19 medicine Paxlovid hits the market at a steep $1,400, sparking concerns

    October 21, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    Pharmaceutical giant Pfizer has announced its intention to charge $1,400 for a five-day course of its antiviral drug Paxlovid. This marks a significant increase from the $529 the US government previously paid for the same quantity of the drug during the pandemic. The Wall Street Journal reports that Pfizer communicated the new pricing in a letter to clinics and pharmacies.

    Pfizer's COVID-19 medicine Paxlovid hits the market at a steep $1,400, sparking concerns

    Despite the hike, insured patients are expected to bear a lesser burden due to insurance coverage. Additionally, Pfizer is anticipated to offer financial aid to patients, including discounts and assistance with out-of-pocket expenses. Pfizer has seen considerable profits from its COVID-related products, especially its mRNA vaccines. However, critics argue that the company’s success in the vaccine market wouldn’t have been possible without the significant public investment in mRNA technology.

    The US government’s expenditure on COVID vaccine development is estimated to range between $18 billion to $39.5 billion, as per the Congressional Budget Office. While Pfizer’s partner, BioNTech, received a $445 million grant from the German government, the US directly funded other companies like Moderna and Johnson & Johnson. Many experts attribute the rapid market introduction of Pfizer’s vaccine to advances in mRNA research.

    Pfizer justifies the Paxlovid pricing based on the drug’s role in reducing COVID-19-related hospitalizations and deaths. A spokesperson from Pfizer stated that all Paxlovid doses labeled for “emergency use authorization” would remain free for patients until the end of 2023. Furthermore, the company has committed to providing the drug free of charge to Medicare, Medicaid, and uninsured patients through a US Government patient assistance program until 2024.

    Despite these assurances, the price hike has been met with criticism. Epidemiologist Eric Feigl-Ding commented that Pfizer’s decision was “shameful” and accused the company of excessive greed. Pfizer’s shares subsequently dipped during Thursday’s trading session. Pfizer’s move comes after other pharmaceutical companies, like Moderna, increased their vaccine prices. While the US government initially paid $19.50 per dose for Pfizer/BioNTech’s vaccine, the revised price for the updated version reached $30.50 per dose.

    In contrast, Moderna priced a single vaccine dose at $130, four times more than the US government’s cost. Amid these changes, Pfizer recently lowered its sales forecast for both Paxlovid and its vaccine developed with BioNTech, attributing the decrease to reduced demand for pandemic-related products. Pfizer’s CEO, Dr. Albert Bourla, acknowledged the nation’s “COVID fatigue” and announced a $3.5 billion cost-cutting initiative for the company.

    Related Posts

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026

    WHO reports 67 yellow fever cases in nine African countries

    November 7, 2026

    Bangladesh dengue deaths reach 418 after deadliest month of 2026

    November 2, 2026

    DR Congo Ebola death toll climbs to 5,340 as cases reach 10,351

    November 2, 2026

    DR Congo Ebola cases top 10,000 in fastest-growing outbreak

    October 28, 2026

    Zambezi Region records 33,944 malaria cases since January

    October 26, 2026
    Breaking News

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026

    – The Ebola outbreak in the Democratic Republic of the Congo is still not under control six months after it was declared, the Africa Centres for Disease Control and Prevention said. Africa CDC Director-General Jean Kaseya told Reuters on Sunday

    UAE and Timor-Leste presidents discuss stronger bilateral ties

    November 16, 2026

    UAE President, Arab League chief discuss regional security

    November 14, 2026

    Morocco secures €434.4 million AfDB loan for reforms

    November 14, 2026

    China, Türkiye and Ethiopia launch carbon credit initiative

    November 13, 2026

    ATI secures Manila South Harbour concession to 2063

    November 13, 2026

    EU and Nigeria sign agreement to speed up migrant returns

    November 12, 2026

    Southeast Asia needs $7.1 trillion for infrastructure by 2040

    November 12, 2026

    Modi tells Zelenskyy India ready to help end Ukraine conflict

    November 11, 2026
    © 2023 Arab Enquirer | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.